Palobiofarma has received FDA approval to initiate a Phase I clinical trial with the novel adenosine A2b antagonist PBF-1129 in lung cancer patients. The trial will be conducted at Ohio State University Comprehensive Cancer Center, Ohio, USA.
FDA grants Palobiofarma approval to start second anti-cancer study in USA

Recent News
- Palobiofarma Presents Phase 2 Results for Investigational PBF-999 in Prader-Willi Syndrome
- Palobiofarma announces significant advances in the clinical development of PBF-999 for Prader-Willi Syndrome
- Palobiofarma announce several important milestones dealing with the clinical development of PBF-999 for Prader-Willi Syndrome
- Palobiofarma Announces Completion of Dual A2A/H3 Receptor Antagonist Research Project for Parkinson’s Disease
- Palobiofarma and Medibiofarma open new headquarters in the AIN building in Cordovilla, Spain

